III期子宫癌辅助治疗后的毒性反应
基于SEER-Medicare数据库,纳入2000至2015年65岁以上III期子宫癌术后接受辅助化疗、放疗或放化疗的2185例患者。放化疗较单模式治疗死亡风险更低,早期毒性高于放疗但与化疗相似,晚期毒性三组相似。
要点
- 放化疗较单纯化疗或放疗降低总死亡风险(aHR分别为1.27和1.25)。
- 放疗早期毒性风险低于放化疗(6个月aRR=0.59,12个月aRR=0.76)。
- 化疗与放化疗的早期和晚期毒性风险相似。
核心结论
- 放化疗与较低的总死亡风险相关,早期和晚期毒性风险与化疗相似,但早期毒性风险高于放疗。
研究设计与样本
- 回顾性队列研究,使用SEER-Medicare数据库纳入2000至2015年65岁及以上III期子宫癌接受辅助化疗、放疗或放化疗的患者共2185例。
主要发现
- 共2185例患者,其中化疗574例(26.3%),放疗636例(29.1%),放化疗975例(44.6%)。
- 接受放化疗或化疗的患者比例随时间增加。
- 辅助治疗前6个月,放疗较放化疗早期毒性风险更低(aRR=0.59,95%CI 0.49-0.70)。
- 辅助治疗前12个月,放疗较放化疗早期毒性风险更低(aRR=0.76,95%CI 0.67-0.86)。
- 化疗与放化疗的早期毒性风险相似;化疗和放疗与放化疗的晚期毒性风险相似。
关键数值与推荐
- 化疗较放化疗总死亡风险更高(aHR=1.27,95%CI 1.10-1.47)。
- 放疗较放化疗总死亡风险更高(aHR=1.25,95%CI 1.08-1.44)。
临床怎么用
- 对于65岁以上III期子宫癌患者,放化疗较单模式治疗可能改善生存,但需权衡早期毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal adjuvant therapy for stage III endometrial cancer is unknown. Studies have suggested that combination therapy with chemotherapy and radiation is associated with improved survival. We examined early and late-term toxicities associated with chemotherapy (CT), external beam radiotherapy (RT), or combination chemoradiotherapy for stage III uterine cancer. METHODS: The SEER-Medicare database was used to identify women age ≥ 65 years with stage III uterine cancer who received adjuvant CT, RT, or chemoradiotherapy from 2000 to 2015. The associations between therapy and early and late-term toxicities identified with billing claims, hospitalizations and emergency department visits were examined using multivariable regression models. RESULTS: A total of 2185 patients were identified including 574 (26.3%) who received CT, 636 (29.1%) who received RT, and 975 (44.6%) who received chemoradiotherapy. The proportion of patients receiving chemoradiotherapy or CT increased over time. During the first 6 and 12 months of adjuvant therapy, RT was associated with a lower risk of early-term toxicity compared to chemoradiotherapy (aRR = 0.59, 95%CI 0.49-0.70 and aRR = 0.76, 95%CI 0.67-0.86, respectively) while CT shared a similar risk of early toxicities as chemoradiotherapy. CT and RT shared a similar risk of late-term toxicities compared to chemoradiotherapy. CT and RT alone were associated with a higher hazard for overall mortality than chemoradiotherapy (aHR = 1.27, 95% CI 1.10-1.47 and aHR = 1.25, 95% CI 1.08-1.44, respectively). CONCLUSION: Chemoradiotherapy is associated with lower mortality compared to single modality therapy and has a similar risk of early and late term toxicities compared to CT, though higher risk of early toxicities compared to RT.
引用
- Chen LC, Huang Y, Hou JY, et al. Toxicity after adjuvant therapy for stage III uterine cancer. Gynecol Oncol. 2020. PMID: 33008633. doi:10.1016/j.ygyno.2020.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。